Xi Su

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms

Xi Su, Zhen Shen, Qi Yang et al. · Theranostics · 2019 · 247 citations · Full text

Medicine, Oncology, Pharmacology +15

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The noncoding RNAs SNORD50A and SNORD50B-mediated TRIM21-GMPS interaction promotes the growth of p53 wild-type breast cancers by degrading p53

Xi Su, Chao Feng, Simeng Wang et al. · Cell Death and Differentiation · 2021 · 58 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Turning a Luffa Protein into a Self-Assembled Biodegradable Nanoplatform for Multitargeted Cancer Therapy

Wangxiao He, Jin Yan, Fang Sui et al. · ACS Nano · 2018 · 51 citations

Pharmacy, Cancer Biology, Oncology +17